Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer
Introduction Triplet regimen of carboplatin or cisplatin with pemetrexed and pembrolizumab is a standard treatment for patients with advanced, chemo-naïve, non-squamous non-small cell lung cancer. However, subgroup analysis for patients aged ≥75 years indicated that elderly patients who received the...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-07-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/10/7/e037746.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846141076237189120 |
|---|---|
| author | Nobuyuki Yamamoto Yuichi Ozawa Takeya Sugimoto Yuichiro Azuma Yuhei Harutani Takanori Yoshikawa Kuninobu Kanai |
| author_facet | Nobuyuki Yamamoto Yuichi Ozawa Takeya Sugimoto Yuichiro Azuma Yuhei Harutani Takanori Yoshikawa Kuninobu Kanai |
| author_sort | Nobuyuki Yamamoto |
| collection | DOAJ |
| description | Introduction Triplet regimen of carboplatin or cisplatin with pemetrexed and pembrolizumab is a standard treatment for patients with advanced, chemo-naïve, non-squamous non-small cell lung cancer. However, subgroup analysis for patients aged ≥75 years indicated that elderly patients who received the triplet regimen may have had shorter survival times than if they had chemotherapy alone (HR of 2.09). Treatments in the elderly are not always as effective or safe as for non-elderly patients, so there remains concern over whether the triplet regimen can be widely used in the elderly.Methods and analysis This is a single-arm, prospective, multicentre phase II study. The primary endpoint is set as the overall response rate according to Response Evaluation Criteria in Solid Tumors V.1.1. Secondary endpoints are progression-free survival, disease control rate and safety. This trial will enrol 22 patients.Ethics and dissemination This study was approved by the Wakayama Medical University Central Review Board on 2 December 2019 (approval number: W-32). Patients have been enrolled since February 2020. As the study will complete accrual in January 2022, results will be submitted for publication in peer-reviewed medical journals within 2023 and international scientific meetings. This study will provide significant information on whether the triplet regimens are clinically beneficial to elderly patients.Trial registration number Japan Registry of Clinical Trials (jRCTs051190095). |
| format | Article |
| id | doaj-art-9c2038878ed14ed7b537c26e00ac1389 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2020-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-9c2038878ed14ed7b537c26e00ac13892024-12-04T21:15:09ZengBMJ Publishing GroupBMJ Open2044-60552020-07-0110710.1136/bmjopen-2020-037746Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancerNobuyuki Yamamoto0Yuichi Ozawa1Takeya Sugimoto2Yuichiro Azuma3Yuhei Harutani4Takanori Yoshikawa5Kuninobu Kanai62 Department of Surgery, Kansai Medical University, Hirakata, Osaka, JapanInternal Medicine III, Wakayama Medical University, Wakayama, JapanInternal Medicine III, Wakayama Medical University, Wakayama, JapanDepartment of Respiratory Medicine, National Hospital Organization Wakayama Hospital, Mihama, JapanDepartment of Respiratory Medicine, National Hospital Organization Minami Wakayama Medical Center, Tanabe, JapanClinical Study Support Center, Wakayama Medical University, Wakayama, JapanDepartment of Respiratory Medicine, Naga Municipal Hospital, Kinokawa, JapanIntroduction Triplet regimen of carboplatin or cisplatin with pemetrexed and pembrolizumab is a standard treatment for patients with advanced, chemo-naïve, non-squamous non-small cell lung cancer. However, subgroup analysis for patients aged ≥75 years indicated that elderly patients who received the triplet regimen may have had shorter survival times than if they had chemotherapy alone (HR of 2.09). Treatments in the elderly are not always as effective or safe as for non-elderly patients, so there remains concern over whether the triplet regimen can be widely used in the elderly.Methods and analysis This is a single-arm, prospective, multicentre phase II study. The primary endpoint is set as the overall response rate according to Response Evaluation Criteria in Solid Tumors V.1.1. Secondary endpoints are progression-free survival, disease control rate and safety. This trial will enrol 22 patients.Ethics and dissemination This study was approved by the Wakayama Medical University Central Review Board on 2 December 2019 (approval number: W-32). Patients have been enrolled since February 2020. As the study will complete accrual in January 2022, results will be submitted for publication in peer-reviewed medical journals within 2023 and international scientific meetings. This study will provide significant information on whether the triplet regimens are clinically beneficial to elderly patients.Trial registration number Japan Registry of Clinical Trials (jRCTs051190095).https://bmjopen.bmj.com/content/10/7/e037746.full |
| spellingShingle | Nobuyuki Yamamoto Yuichi Ozawa Takeya Sugimoto Yuichiro Azuma Yuhei Harutani Takanori Yoshikawa Kuninobu Kanai Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer BMJ Open |
| title | Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer |
| title_full | Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer |
| title_fullStr | Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer |
| title_full_unstemmed | Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer |
| title_short | Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer |
| title_sort | prospective multicentre single arm phase ii trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced non squamous non small cell lung cancer |
| url | https://bmjopen.bmj.com/content/10/7/e037746.full |
| work_keys_str_mv | AT nobuyukiyamamoto prospectivemulticentresinglearmphaseiitrialofpembrolizumabcombinedwithcarboplatinandpemetrexedinelderlypatientswithadvancednonsquamousnonsmallcelllungcancer AT yuichiozawa prospectivemulticentresinglearmphaseiitrialofpembrolizumabcombinedwithcarboplatinandpemetrexedinelderlypatientswithadvancednonsquamousnonsmallcelllungcancer AT takeyasugimoto prospectivemulticentresinglearmphaseiitrialofpembrolizumabcombinedwithcarboplatinandpemetrexedinelderlypatientswithadvancednonsquamousnonsmallcelllungcancer AT yuichiroazuma prospectivemulticentresinglearmphaseiitrialofpembrolizumabcombinedwithcarboplatinandpemetrexedinelderlypatientswithadvancednonsquamousnonsmallcelllungcancer AT yuheiharutani prospectivemulticentresinglearmphaseiitrialofpembrolizumabcombinedwithcarboplatinandpemetrexedinelderlypatientswithadvancednonsquamousnonsmallcelllungcancer AT takanoriyoshikawa prospectivemulticentresinglearmphaseiitrialofpembrolizumabcombinedwithcarboplatinandpemetrexedinelderlypatientswithadvancednonsquamousnonsmallcelllungcancer AT kuninobukanai prospectivemulticentresinglearmphaseiitrialofpembrolizumabcombinedwithcarboplatinandpemetrexedinelderlypatientswithadvancednonsquamousnonsmallcelllungcancer |